Mineralized Tissue: Histology, Biology and Biochemistry - Osteogenesis Imperfecta - page 36

[45] Kozloff KM, Carden A, Bergwitz C, et al. Brittle IV mouse model
for osteogenesis imperfecta IV demonstrates postpubertal adap-
tations to improve whole bone strength. J Bone Miner Res
2004;19:614-22.
[46] Goldberg M, Kulkarni AB, Young M, Boskey A. Dentin: struc-
ture, composition and mineralization. Front Biosci (Elite Ed)
2011;3:711-35.
[47] Daley E, Streeten EA, Sorkin JD, et al. Variable bone fragil-
ity associated with an Amish COL1A2 variant and a knock-in
mouse model. J Bone Miner Res 2010;25:247-61.
[48] Camacho NP, Landis WJ, Boskey AL. Mineral changes in a mouse
model of osteogenesis imperfecta detected by Fourier transform
infrared microscopy. Connect Tissue Res 1996;35:259-65.
[49] Misof BM, Roschger P, Baldini T, et al. Differential effects of
alendronate treatment on bone from growing osteogenesis
imperfecta and wild-type mouse. Bone 2005;36:150-8.
[50] Vetter U, Eanes ED, Kopp JB, Termine JD, Robey PG. Changes in
apatite crystal size in bones of patients with osteogenesis imper-
fecta. Calcif Tissue Int 1991;49:248-50.
[51] Donnelly E, Meredith DS, Nguyen JT, Boskey AL. Bone tissue
composition varies across anatomic sites in the proximal femur
and the iliac crest. J Orthop Res 2012;30:700-6.
[52] Gourion-Arsiquaud S, Burket JC, Havill LM, et al. Spatial varia-
tion in osteonal bone properties relative to tissue and animal
age. J Bone Miner Res 2009;24:1271-81.
[53] Vetter U, Weis MA, Mörike M, Eanes ED, Eyre DR. Collagen
crosslinks and mineral crystallinity in bone of patients with
osteogenesis imperfecta. J Bone Miner Res 1993;8:133-7.
[54] Coleman RM, Aguilera L, Quinones L, Lukashova L, Poirier C,
Boskey AL. Elucidating the mineralization defect of osteogen-
esis imperfecta: comparison of mouse models with collagenous
and non-collagenous genetic mutations. Bone 2012;51:920-8.

[65] Verdelis K, Lukashova L, Atti E, et al. MicroCT morphom-

etry analysis of mouse cancellous bone: intra- and inter-system
reproducibility. Bone 2011;49:580-7.

[66] Bargman R, Posham R, Boskey AL, DiCarlo E, Raggio C,

Pleshko N. Comparable outcomes in fracture reduction and
bone properties with RANKL inhibition and alendronate treat-
ment in a mouse model of osteogenesis imperfect. Osteoporos
Int 2012;23:1141-50.

[67] Roemer FW, Mohr A, Guermazi A, et al. Phenotypic character-

ization of skeletal abnormalities of Osteopotentia mutant mice
by micro-CT: a descriptive approach with emphasis on recon-
struction techniques. Skeletal Radiol 2011;40:1073-8.

[68] Mehrotra M, Rosol M, Ogawa M, Larue AC. Amelioration of a

mouse model of osteogenesis imperfecta with hematopoietic
stem cell transplantation: microcomputed tomography studies.
Exp Hematol 2010;38:593-602.

[69] Liu XS, Cohen A, Shane E, et al. Bone density, geometry, micro-

structure, and stiffness: relationships between peripheral and
central skeletal sites assessed by DXA, HR-pQCT, and cQCT in
premenopausal women. J Bone Miner Res 2010;25:2229-38.

[70] Rauch F, Lalic L, Roughley P, Glorieux FH. Relationship between

genotype and skeletal phenotype in children and adolescents
with osteogenesis imperfecta. J Bone Miner Res 2010;25:1367-74.

[71] Rauch F, Lalic L, Roughley P, Glorieux FH. Genotype-phenotype

correlations in nonlethal osteogenesis imperfecta caused by
mutations in the helical domain of collagen type I. Eur J Hum
Genet 2010;18:642-7.

[72] Marini JC, Cabral WA, Barnes AM. Null mutations in LEPRE1

and CRTAP cause severe recessive osteogenesis imperfecta. Cell
Tissue Res 2010;339:59-70.

[73] Marini JC, Forlino A, Cabral WA, et al. Consortium for osteogen-

esis imperfecta mutations in the helical domain of type I collagen:
regions rich in lethal mutations align with collagen binding sites
for integrins and proteoglycans. Hum Mutat 2007;28:209-21.

[55] Fratzl P, Paris O, Klaushofer K, Landis WJ. Bone mineralization

in an osteogenesis imperfecta mouse model studied by small-
angle x-ray scattering. J Clin Invest 1996;97:396-402. [74] Vetter U, Fisher LW, Mintz KP, et al. Osteogenesis imperfecta:

changes in noncollagenous proteins in bone. J Bone Miner Res
1991;6:501-5.

[56] Grabner B, Landis WJ, Roschger P, et al. Age- and genotype-

dependence of bone material properties in the osteogenesis
imperfecta murine model (oim). Bone 2001;29:453-7. [75] Martinek N, Shahab J, Sodek J, Ringuette M. Is SPARC an evo-

lutionarily conserved collagen chaperone? J Dent Res 2007;
86:296-305.

[57] Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone min-

eralization density distribution in health and disease. Bone
2008;42:456-66. [76] Fujisawa R, Tamura M. Acidic bone matrix proteins and their

roles in calciication. Front Biosci 2012;17:1891-903. [58] Fratzl-Zelman N, Morello R, Lee B, et al. CRTAP deiciency leads

to abnormally high bone matrix mineralization in a murine model
and in children with osteogenesis imperfecta type VII. Bone
2010;46:820-6.

[77] Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M. Fetuin-A

regulation of calciied matrix metabolism. Circ Res 2011;
108:1494-509.

[59] Cassella JP, Pereira R, Prockop DJ, Ali SY. Mineral changes in a

transgenic mouse model for osteogenesis imperfecta. Br J Biomed
Sci 1996;53:108-15.

[78] Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK,

Goldberg HA. Bone sialoprotein expression enhances osteoblast
differentiation and matrix mineralization in vitro. Bone 2007;
41:462-73. [60] Woessner Jr JF. The determination of hydroxyproline in tissue

and protein samples containing small proportions of this imino
acid. Arch Biochem Biophys 1961;93:440-7.

[79] Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, Goldberg

HA. Nucleation and inhibition of hydroxyapatite formation by
mineralized tissue proteins. Biochem J 1996;317:59-64. [61] Carleton SM, McBride DJ, Carson WL, et al. Role of genetic

background in determining phenotypic severity throughout
postnatal development and at peak bone mass in Col1a2 dei-
cient mice (oim). Bone 2008;42:681-94.

[80] Wade-Gueye NM, Boudiffa M, Vanden-Bossche A, et al.

Absence of bone sialoprotein (BSP) impairs primary bone for-
mation and resorption: the marrow ablation model under PTH
challenge. Bone 2012;50:1064-73. [62] Cassella JP, Garrington N, Stamp TC, Ali SY. An electron probe

X-ray microanalytical study of bone mineral in osteogenesis
imperfecta. Calcif Tissue Int 1995;56:118-22.

[81] Muriel MP, Bonaventure J, Stanescu R, Maroteaux P, Guénet JL,

Stanescu V. Morphological and biochemical studies of a mouse
mutant (fro / fro) with bone fragility. Bone 1991;12:241-8. [63] Sarathchandra P, Kayser MV, Ali SY. Abnormal mineral composi-

tion of osteogenesis imperfecta bone as determined by electron
probe X-ray microanalysis on conventional and cryosections.
Calcif Tissue Int 1999;65:11-55.

[82] Fedarko NS, Robey PG, Vetter UK. Extracellular matrix stoichi-

ometry in osteoblasts from patients with osteogenesis imper-
fecta. J Bone Miner Res 1995;10:1122-9.

[64] Phillips CL, Bradley DA, Schlotzhauer CL, et al. Oim mice

exhibit altered femur and incisor mineral composition and
decreased bone mineral density. Bone 2000;27:219-26.

[83] Hynes RO, Naba A. Overview of the matrisome - an inventory of

extracellular matrix constituents and functions. Cold Spring Harb
Perspect Biol 2012;4:a004903. doi:10.1101 / cshperspect.a004903.